RDCA Delhi seeks 24x7 unrestricted movement for pharma supplies to ensure uninterrupted patient care
RDCA Delhi seeks 24x7 unrestricted movement for pharma supplies to ensure uninterrupted patient care: Peethaambaran ...
Nutraceuticals gain shelf presence through pharmacist advocacy, clean labelling & smart retail tie-ups: Nandita Vijayasimha, Bengaluru Tuesday, March 31, 2026, 08:00 Hrs [IST] Nut ...
IPA Kerala joins nationwide protest against DTAB recommendation on competent persons: Peethaambaran Kunnathoor, Chennai Tuesday, March 31, 2026, 08:00 Hrs [IST] The Kerala State B ...
Panel recommends time-bound measures to fill vacant posts in CDSCO: Gireesh Babu, New Delhi Tuesday, March 31, 2026, 08:00 Hrs [IST] The Parliamentary Panel on Health and Family W ...
CDSCO streamlines processing of written confirmation for export of APIs to EU: Gireesh Babu, New Delhi Tuesday, March 31, 2026, 08:00 Hrs [IST] The Central Drugs Standard Control ...
ORIC Pharma to report combination dose optimization data from phase 1b trial of rinzimetostat in patients with mCRPC: South San Francisco, California Monday, March 30, 2026, 18:00 ...
HRV Global Life Sciences and Shodhana Laboratories ink strategic CDMO pact to fast-track high-science & next-generation API development: Our Bureau, Bengaluru Monday, March 30, 20 ...
CDSCO asks SLAs to keep vigil on unlicensed IVF devices in the market: Our Bureau, New Delhi Monday, March 30, 2026, 14:15 Hrs [IST] The Central Drugs Standard Control Organisatio ...
US FDA clears Lantern Pharma and Starlight Therapeutics’ IND for a planned phase 1 paediatric CNS cancer trial of STAR-001: Dallas Monday, March 30, 2026, 14:00 Hrs [IST] Lanter ...
Fortis Hiranandani Hospital Navi Mumbai champions next-gen learning in gynaecological endoscopy for young obgyns across Mumbai: Our Bureau, Mumbai Monday, March 30, 2026, 17:30 Hr ...
EMA recommends marketing authorisation in EU for Imdylltra to treat adults with extensive-stage small cell lung cancer: Amsterdam, The Netherlands Monday, March 30, 2026, 17:00 Hr ...
Editas Medicine announces USPTO reaffirms its prior decision in favour of the Broad Institute in CRISPR/Cas9 interference: Cambridge, Massachusetts Monday, March 30, 2026, 15:00 H ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results